
Deciphera Pharmaceuticals, Inc. – NASDAQ:DCPH
Deciphera Pharmaceuticals stock price monthly change
Deciphera Pharmaceuticals stock price quarterly change
Deciphera Pharmaceuticals stock price yearly change
Deciphera Pharmaceuticals key metrics
Market Cap | 2.21B |
Enterprise value | 1.07B |
P/E | -6.62 |
EV/Sales | 8.00 |
EV/EBITDA | -6.28 |
Price/Sales | 8.27 |
Price/Book | 3.24 |
PEG ratio | -0.12 |
EPS | -2.21 |
Revenue | 174.91M |
EBITDA | -203.92M |
Income | -190.41M |
Revenue Q/Q | 34.54% |
Revenue Y/Y | 26.50% |
Profit margin | -133.49% |
Oper. margin | -136.32% |
Gross margin | 93.46% |
EBIT margin | -136.32% |
EBITDA margin | -116.59% |
create your own Smart Feed
Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.
Sign up for freeDeciphera Pharmaceuticals stock price history
Deciphera Pharmaceuticals stock forecast
Deciphera Pharmaceuticals financial statements
Jun 2023 | 38.30M | -48.56M | -126.78% |
---|---|---|---|
Sep 2023 | 43.31M | -49.58M | -114.47% |
Dec 2023 | 48.29M | -47.19M | -97.71% |
Mar 2024 | 44.99M | -45.08M | -100.19% |
Mar 2024 | 44.99M | -45.08M | -100.19% |
---|---|---|---|
Sep 2025 | 66.8M | -27.74M | -41.53% |
Oct 2025 | 62.53M | -36.41M | -58.23% |
Dec 2025 | 72.5M | -27.09M | -37.37% |
Analysts Price target
Financials & Ratios estimates
2023-05-03 | -0.6 | -0.6 |
---|
Jun 2023 | 509618000 | 105.18M | 20.64% |
---|---|---|---|
Sep 2023 | 497836000 | 116.16M | 23.33% |
Dec 2023 | 473566000 | 122.65M | 25.9% |
Mar 2024 | 420928000 | 104.87M | 24.92% |
Jun 2023 | -38.62M | 4.36M | 838K |
---|---|---|---|
Sep 2023 | -29.80M | 41.40M | 15.59M |
Dec 2023 | -28.80M | 2.19M | 890K |
Mar 2024 | -54.58M | 62.63M | 522K |
Deciphera Pharmaceuticals alternative data
Aug 2023 | 300 |
---|---|
Sep 2023 | 300 |
Oct 2023 | 300 |
Nov 2023 | 300 |
Dec 2023 | 300 |
Jan 2024 | 300 |
Feb 2024 | 300 |
Mar 2024 | 355 |
Apr 2024 | 355 |
May 2024 | 355 |
Jun 2024 | 355 |
Jul 2024 | 355 |
Deciphera Pharmaceuticals other data
Period | Buy | Sel |
---|---|---|
Mar 2023 | 0 | 7500 |
May 2023 | 11000 | 0 |
Jun 2023 | 10000 | 7441 |
Oct 2023 | 0 | 32005 |
Nov 2023 | 0 | 17801 |
Dec 2023 | 0 | 39637 |
Jan 2024 | 0 | 8118 |
Feb 2024 | 0 | 10159 |
Transaction | Date | Insider | Security | Shares | Price per share | Total value | Source |
---|---|---|---|---|---|---|---|
Sale | SHERMAN MATTHEW L officer: EVP & Ch.. | Common Stock | 2,615 | $15.62 | $40,841 | ||
Sale | KELLY THOMAS PATRICK officer: Chief Fi.. | Common Stock | 3,010 | $15.62 | $47,010 | ||
Sale | PITMAN JAMA officer: SVP, Chief Development.. | Common Stock | 2,267 | $15.62 | $35,406 | ||
Sale | MARTIN DANIEL C. officer: Chief Co.. | Common Stock | 2,267 | $15.62 | $35,406 | ||
Sale | SHERMAN MATTHEW L officer: EVP & Ch.. | Common Stock | 2,435 | $14.47 | $35,234 | ||
Sale | PITMAN JAMA officer: SVP, Chief Development.. | Common Stock | 1,624 | $14.47 | $23,499 | ||
Sale | MARTIN DANIEL C. officer: Chief Co.. | Common Stock | 1,624 | $14.47 | $23,499 | ||
Sale | KELLY THOMAS PATRICK officer: Chief Fi.. | Common Stock | 2,435 | $14.47 | $35,234 | ||
Sale | HOERTER STEVEN L. director, officer.. | Common Stock | 30,664 | $15.37 | $471,214 | ||
Sale | KELLY THOMAS PATRICK officer: Chief Fi.. | Common Stock | 2,792 | $15.37 | $42,905 |
Quarter | Transcript |
---|---|
Q4 2023 6 Feb 2024 | Q4 2023 Earnings Call Transcript |
Q2 2023 9 Aug 2023 | Q2 2023 Earnings Call Transcript |
Q1 2023 7 May 2023 | Q1 2023 Earnings Call Transcript |
Q4 2022 7 Feb 2023 | Q4 2022 Earnings Call Transcript |
Deciphera: Upside Potential For The Patient Investor
Deciphera Pharmaceuticals: Moving The Needle Where It Counts
Deciphera Pharmaceuticals Pipeline Is Underwhelming
Deciphera Pharmaceuticals: Clawing Its Way Back
Deciphera Is A Buy In Expectation Of A Significant Comeback
Deciphera Pharmaceuticals: In The Middle Of A Major Comeback (Upgrade)
Deciphera Pharmaceuticals: INTRIGUE Phase 3 Shows Substantial Benefit
Deciphera Pharmaceuticals: The 75% Haircut Doesn't Seem Justified
ASCO 2021: A Plethora Of Cancer Therapeutic Investment Ideas
-
When is Deciphera Pharmaceuticals's next earnings date?
Unfortunately, Deciphera Pharmaceuticals's (DCPH) next earnings date is currently unknown.
-
Does Deciphera Pharmaceuticals pay dividends?
No, Deciphera Pharmaceuticals does not pay dividends.
-
How much money does Deciphera Pharmaceuticals make?
Deciphera Pharmaceuticals has a market capitalization of 2.21B and it's past years’ income statements indicate that its last revenue has increased compared to the previous period by 21.87% to 163.36M US dollars. Deciphera Pharmaceuticals made a loss 194.94M US dollars in net income (profit) last year or -$0.6 on an earnings per share basis.
-
What is Deciphera Pharmaceuticals's stock symbol?
Deciphera Pharmaceuticals, Inc. is traded on the NASDAQ under the ticker symbol "DCPH".
-
What is Deciphera Pharmaceuticals's primary industry?
Company operates in the Healthcare sector and Drug Manufacturers - Specialty & Generic industry.
-
How do i buy shares of Deciphera Pharmaceuticals?
Shares of Deciphera Pharmaceuticals can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
-
Who are Deciphera Pharmaceuticals's key executives?
Deciphera Pharmaceuticals's management team includes the following people:
- Mr. Steven L. Hoerter Pres, Chief Executive Officer & Director(age: 54, pay: $1,200,000)
- Dr. Matthew L. Sherman Executive Vice President & Chief Medical Officer(age: 69, pay: $818,410)
- Mr. Thomas Patrick Kelly J.D. Executive Vice President, Chief Financial Officer & Treasurer(age: 54, pay: $726,860)
- Dr. Daniel L. Flynn Ph.D. Executive Vice President, Chief Scientific Officer & Founder(age: 70, pay: $722,510)
- Mr. Daniel C. Martin Senior Vice President & Chief Commercial Officer(age: 50, pay: $707,820)
- Dr. Stephen B. Ruddy Ph.D. Senior Vice President & Chief Technical Officer(age: 61, pay: $601,540)
-
Is Deciphera Pharmaceuticals founder-led company?
Yes, Deciphera Pharmaceuticals is a company led by its founder Dr. Daniel L. Flynn Ph.D..
-
How many employees does Deciphera Pharmaceuticals have?
As Jul 2024, Deciphera Pharmaceuticals employs 355 workers.
-
When Deciphera Pharmaceuticals went public?
Deciphera Pharmaceuticals, Inc. is publicly traded company for more then 7 years since IPO on 28 Sep 2017.
-
What is Deciphera Pharmaceuticals's official website?
The official website for Deciphera Pharmaceuticals is deciphera.com.
-
Where are Deciphera Pharmaceuticals's headquarters?
Deciphera Pharmaceuticals is headquartered at 200 Smith Street, Waltham, MA.
-
How can i contact Deciphera Pharmaceuticals?
Deciphera Pharmaceuticals's mailing address is 200 Smith Street, Waltham, MA and company can be reached via phone at +7 812096400.
Deciphera Pharmaceuticals company profile:

Deciphera Pharmaceuticals, Inc.
deciphera.comNASDAQ
355
Drug Manufacturers - Specialty & Generic
Healthcare
Deciphera Pharmaceuticals, Inc., a biopharmaceutical company, develops drugs to enhance the lives of cancer patients by addressing key mechanisms of drug resistance that limit the rate and durability of response to existing cancer therapies in the United States and internationally. Its lead drug candidate is QINLOCK used for the treatment of gastrointestinal stromal tumors (GIST), as well as in INTRIGUE Phase 3 study to treat second-line GIST. The company is also developing vimseltinib, an orally administered, potent, and highly selective switch-control kinase inhibitor of colony stimulating factor 1 receptor (CSF1R) for the treatment of tenosynovial giant cell tumor (TGCT); and DCC-3116 to treat RAS/RAF mutant cancers that is in the preclinical-stage. Deciphera Pharmaceuticals, Inc. was founded in 2003 and is headquartered in Waltham, Massachusetts.
Waltham, MA 02451
CIK: 0001654151
ISIN: US24344T1016
CUSIP: 24344T101